Mindstate Design Labs

-43%

est. 2Y upside i

HealthcareSeries A

Mindstate Design Labs is a preclinical-stage biotechnology company developing the next generation of psychedelic-inspired therapeutics for intractable mental health conditions.

Rank

#199

Sector

Biotechnology, Drug Discovery

Est. Liquidity

~6Y

Data Quality

Data: Medium

Mindstate Design Labs presents a compelling, albeit high-risk, equity opportunity driven by its innovative AI platform and promising early clinical trial results for 'trip-free' psychedelics.

Last updated: February 23, 2026

Bull (35%)+350%

MSD-001 achieves breakthrough designation, secures a major pharmaceutical partnership, or demonstrates superior efficacy and safety in later-stage trials, leading to a significantly higher valuation.

Base (40%)+100%

Successful progression through clinical trials, securing further funding, and demonstrating continued efficacy.

Bear (25%)-80%

Clinical trials fail, regulatory hurdles prove insurmountable, or a competitor develops a superior solution.

Est. time to liquidity~6.0 years

Preference Stack Risk

high

Investors hold $26M in liquidation preferences ahead of common shareholders, representing 17.3% of the estimated $150M valuation.

Dilution Risk

high

As a clinical-stage biotech, the company will require several more funding rounds to complete trials and commercialize, leading to significant future dilution for common shareholders.

Secondary Liquidity

none

There is currently no active secondary market for shares in this early-stage private company.

Community

Valuation Sentiment

Our model estimates -43% upside. What do you think?

Anonymous. Do not share material non-public information.

Community Discussion

Comments are reviewed before they appear publicly.

Loading comments...

Disclaimer: This analysis is AI-generated and does not constitute financial or career advice. Always conduct your own due diligence.